335 results about "Rabies virus" patented technology

The invention discloses an anti-rabies virus monoclonal antibody and a preparation method and an application, belonging to the field of biomedicine and particularly relating to the preparation of a monoclonal antibody capable of identifying rabies virus and the application. The monoclonal antibody of the invention is screened by indirect Enzyme-linked immunosorbent assay (ELISA), and specificity and affinity thereof combined with antigen are identified by methods such as polyacrylamide gel electrophoresis analysis, speckle ELISA, immunoblot analysis and the like. The anti-rabies virus monoclonal antibody of the invention can be applied in multiple testing methods of antigen of rabies virus and can be also applied in the preparation of rabies virus detecting kit. The anti-rabies virus monoclonal antibody is secreted by anti-rabies virus monoclonal antibody hybridoma cell strain 2C5 with the preservation number being CGMCC No.3014.

The invention discloses a colloidal gold immunochromatographic test strip for detecting wild-type classical swine fever virus, which consists of water absorbent paper (1), a cellulose nitrate membrane (2), a colloidal gold pad (3), a sample pad (4) and a support (5), wherein the cellulose nitrate membrane contains a detection line which is formed by coating monoclonal antibody HQ06 of anti-classical swine fever virus E2 protein and a quality control line which is formed by coating rabbit anti-mouse IgG antibody; and the colloidal gold pad is combined with colloidal gold-labeled monoclonal antibody 6E10 of the anti-classical swine fever virus E2 protein. The test strip does not react with C-strain of classical swine fever virus, bovine viral diarrhea virus, porcine reproductive and respiratory syndrome virus, transmissible gastroenteritis virus, porcine epidemic diarrhea virus, porcine rotavirus, pseudorabies virus, porcine parvovirus and porcine circovirus type 2, and can accurately and sensitively identify the wild-type classical swine fever virus, thereby having good specificity, sensitivity and repeatability.

Production of recombinant human rabies virus mono-cloning antibody NM57 is stable and has high purity and excellent specificity. It can be used to prevent rabies and substitute ERIG and HRIG.

The present invention provides vectors that contain and co-express in vivo or in vitro immunogenic polypeptides or antigens together with an OX40L polypeptide, which functions as a genetic adjuvant. Together, the immunogenic polypeptide and the OX40L polypeptide elicit an immune response in animal or human, which is greater than the immune response elicited by the immunogenic polypeptide alone. In a particular example, the invention provides vectors encoding a Rabies G immunogenic polypeptide and a canine OX40L genetic adjuvant, which vectors elicit strong immune responses in canine against rabies virus

The invention provides a method for extracting rabies virus, and is to solve the defects that great discrepancy of quality indices of different batches occurs; removal of remaining DNA becomes difficult; the protein content of the remaining host is too high; and great side effects appear clinically when the single method of molecular sieve gel chromatography is adopted for extracting rabies virus vaccine. The essential of the invention is that a hollow fiber ultrafiltration column or ultrafiltration membrane with the molecular weight cut-off of 750KD or 500KD is used to condense and partially purify harvested liquid of virus; anion exchange chromatography or molecular sieve gel chromatography is adopted to separate and purify samples; molecular sieve gel chromatography or anion exchange chromatography is adopted to separate and purify samples got in step (2). The method for extracting rabies virus has the characteristics of great productive capacity, high product quality, excellent batch stability, being remarkably effective in removal of remaining DNA and HCP, and reducing the potential safety hazard of vaccine.

Live, attenuated recombinant rabies virus vaccines are generated using reverse genetics to combine the antigenic determinants that render the rabies virus non-pathogenic with the determinants that are responsible for the elicitation of an effective anti-rabies immune response. These vaccines do not affect the antigenic, and therefore the immunogenic, properties of the virus. The present invention further relates to recombinant rabies virus vaccines that express a pro-apoptotic protein, such as cytochrome c, to increase the capacity to induce apoptosis, thereby enhancing the protective immunity against rabies. This new generation of live rabies virus vaccines represents a safe and effective approach to the eradication of rabies in wildlife, and subsequently humans and livestock.

The invention relates to an anthropogenic antivirulin glycosidoprotein neutralizing genetic engineering antibody RD9 and a preparation and an application thereof. The antibody is VH-connecting peptide-VK of a three-structural single-stranded antibody comprising a variable region of heavy chain and a variable region of light chain by using 12 sequences of amino acid of the 1 (CH1) 5' end of a constant region of a heavy chain as the connecting peptide AKTTAPSVYPL, and the antibody realizes efficient expression in a prokaryotic system. The biological characteristic studies show that the RD9 is an anthropogenic genetic engineering antibody which has high appetency and better stability and can specially centralize rabies virus as well as genes and gene products of the antibody can be used for preparing clinical drugs for preventing and treating the rabies; the preparation method of the antibody is easy for massive industrial production. The invention solves the problem in the other technology of the application of genes of the variable region of the heavy chain and the variable region of a light chain of the antibody and polypeptide coded by the genes in the drugs for preventing and treating the rabies.

The invention relates to a kit which utilizes a probe fluorescence quantitative PCR technology, is divided into two systems and can fast obtain and detect a variety of viruses causing porcine reproductive disorders and diarrheal diseases from clinical samples, wherein the A system is used for detecting porcine circovirus type 2 (PCV2), porcine parvovirus (PPV) and pseudorabies virus (PRV); the B system is used for detecting porcine epidemic diarrhea virus (PEDV), porcine reproductive and respiratory syndrome virus (PRRSV) and classical swine fever virus (CSFV). The detection kit is reasonable in design, simple in a using method, fast, accurate and high in sensitivity, is suitable for port inspection and quarantine management, livestock farming, animal protection and other departments, and simultaneously has extensive scientific research values and commercial prospects.

This invention discloses a kind of measuring PRVHS fluorescence quantitative PCR reagent box and application. The reagent box has a) DNA cracking liquid, b)Taq DNA polymerization enzyme, c) pG-HB-contained nucleoside series of standard positive template, d)the fluorescence quantitative reaction liquid containing positive and negative primer and fluorescence probe series. Advantages: simple and easy for operation, fast and accurate quantitation and so on.

The invention belongs to the construction field of auxiliary viruses, and discloses a method and an application of fast retrograde transsynaptic labeling of nerve cells. The invention uses double-stranded adeno-associated virus (SCAAV) as a helper virus vector to load TVA receptor and rabies virus outer membrane glycoprotein (RVG) respectively, and packaged into virus for specific recognition andretrograde transsynaptic marker of ENVA outer membrane wrapped defective recombinant rabies virus. As shown by that live test result, the recombinant defective rabies virus RV-[delta]G-X-ENVA and helper virus SCAAV combined system, can realize fast retrograde transsynaptic labeling, which saves 1-2 week experiment time, saves material resources and manpower, provides a better research tool for theapplication of defective rabies virus in neural network reverse transsynaptic marker, and lays a good technical support for the structure and function analysis of neural network.

The invention relates to a process for preparing a veterinary rabies inactivated vaccine, in particular to a process for preparing a veterinary rabies inactivated and freeze-dried vaccine through a suspension culture cell. The method has the key point that: a bioreactor is used for large-scale suspension culture of baby hamster kidney BHK21-C13 cells and rabies virus is inoculated, and the rabiesvirus is subjected to mass propagation through a fed-batch and perfusion technology, so that a high-concentration and high-titer rabies antigen is obtained and concentrated, inactivated and purified to prepare the veterinary rabies inactivated vaccine; and thus, technical problems such as complexity, low antigen content, low effectiveness, large dosage, poor batch-to-batch variation and the like existing in the conventional process are solved.

The invention demonstrates that, contrary to apoptotic rabies virus G proteins, certain non-apoptotic rabies virus G proteins, such as the G protein of the CVS-NIV strain, have a neurite outgrowth promoting effect. The invention further demonstrates that this neurite outgrowth promoting effect is due to the cytoplasmic tail of said non-apoptotic rabies virus G proteins, more particularly to their PDZ-BS, which shows a single-point mutation compared to the one of apoptotic rabies virus G proteins. The invention provides means for inducing and/or stimulating neurite outgrowth, which are useful in inducing neuron differentiation, for example for the treatment of a neoplasm of the nervous system, as well as in regenerating impaired neurons, for example for the treatment of a neurodegenerative disease, disorder or condition or in the treatment of a microbial infection, or in protecting neurons from neurotoxic agents or oxidative stress.

The invention discloses a time resolved immunofluorescence detection kit for rabies virus nucleoprotein, and a preparation method thereof. The content of rabies virus nucleoprotein in a sample is quantificationally determined by using principles of a double-antibody sandwich method and time resolved immunofluorescence. The detection kit comprises a standard, a coating reaction plate, a lanthanide ion marked anti-rabies virus nucleoprotein monoclonal antibody, an analysis buffer, a washing liquid and a fluorescence enhancing liquid, wherein a first anti-rabies virus nucleoprotein monoclonal antibody is adsorbed on the coating reaction plate, and a second anti-rabies virus nucleoprotein monoclonal antibody is marked with the lanthanide ion. A preparation method comprises: adding a to-be measured sample in the coating reaction plate, incubating, washing, adding the lanthanide ion marked second anti-rabies virus nucleoprotein monoclonal antibody, incubating, washing, adding the fluorescence enhancing liquid, and determining in a time resolved immunofluorescence detector. The technical scheme of the invention has advantages of high sensitivity, good singularity, simple operation, wide detection scope and the like.

The invention discloses a humanized neutralizing antibody (RVFab8) against rabies virus glycoprotein, which is obtained through screening by utilizing phage display technology. The antibody specifically identifies the granule antigen of the rabies virus, is against the rabies virus glycoprotein G, has obvious immunofluorescence reaction and enzyme linked immunosorbent assay with the rabies virus and has the neutralizing activity function against rabies virus infection. The antibody can be prepared into the specific antibody drugs for preventing and treating rabies, thereby being clinically used for preventing and treating rabies caused by the rabies virus.

The invention provides a recombinant rabies viruses comprising three copies of a mutated G gene wherein each G gene encodes a rabies virus glycoprotein having the amino acid 194 mutated to a serine and the amino acid 333 is mutated to a glutamic acid. The recombinant rabies virus is nonpathogenic in immunodeficient mammals and can be used in a vaccine to induce an immune response protect mammals from infection by rabies virus as well as clear a pre-existing rabies virus infection from neural tissues.

The invention discloses a completely humanized neutralizing antibody for anti-rabies viruses. The amino acid sequence of a heavy chain of the antibody is shown in sequence table SEQ ID NO1, the amino acid sequence of a light chain of the antibody is shown in sequence table SEQ ID NO5, the complementary determining region (CDR) of a variable region of the heavy chain of the antibody is shown as follows: CDR1: SEQIDNO2, CDR2:SEQIDNO3 and CDR3: SEQIDNO4, and the complementary determining region (CDR) of a variable region of the light chain of the antibody is shown as follows: CDR1:SEQIDNO6, CDR2:SEQIDNO7, and CDR3: SEQIDNO8. The beneficial effects of the completely humanized neutralizing antibody are that: the completely humanized neutralizing antibody disclosed by the invention ahs the advantages of being completely humanized, good in specificity, high in affinity, good in neutralizing effect, and low in price, can be used as a biological engineering antibody drug to quickly establish immune protection force against rabies virus, can be used for passive immunotherapy of acute infection, and also can be used for preparing detection reagents for detecting the rabies virus, finding effective neutralization antigen epitope and developing recombinant proteins and subunit vaccines for the rabies virus.

The invention discloses a preparation method and application of a Cre and Flp dependent retrograde tracing recombinant pseudo-rabies virus. The preparation method comprises the following steps: (1) preparing a Cre and Flp system dependant retrograde tracing recombinant pseudo-rabies virus; and (2) using the virus in a labeled neural circuit, and successfully preparing a recombinant pseudo-rabies virus with independent and controllable Cre and Flp by the platform. The preparation method successfully obtains recombinant pseudo-rabies virus with independent Cre and Flp that can express fluorescent protein. The virus can be widely used in neural circuit labeling, establishment of drug screening platform, study on virus inhibiting mechanism of drugs, development of viral vaccine and diagnosticreagent, establishment of animal model, virus replication, analysis of pathogenic mechanism, and the like.

The present invention pertains to antigenic peptides of rabies virus and their use in the detection, prevention and/or treatment of conditions resulting from rabies virus.

The invention relates to a rabies virus Flury-LEP vaccine strain reverse genetic operating system comprising a recombination vector for coding LEP full length genome cDNA and an auxiliary plasmid system thereof, wherein, the auxiliary plasmid system respectively codes nucleoprotein of LEP, phosphoric acid protein P and polyase protein L. the invention also relates to LEP green fluorescent protein recombination viral vector built by the reverse genetic operating system, concretely, the rabies virus Flury-LEP vaccine strain reverse genetic operating system is pCI-LEP and auxiliary plasmid systems pCAGG-N, pCAGG-P and pCAGG-L, the LEP green fluorescent protein recombination viral vector is pCI_LEP_EGEP. The invention also relates to recombination viruses rescued by the rabies virus Flury-LEP vaccine strain reverse genetic operating system and the LEP green fluorescent protein recombination viral vector, and applications thereof.

The invention relates to a Newcastle disease LaSota lentogen vaccine which expresses rabiesvirus glycosidoprotein (GP protein); more specifically, the Newcastle disease LaSota lentogen vaccine is rL-ERAGP. The invention also discloses a method for preparing the Newcastle disease LaSota lentogen vaccine and an application of the Newcastle disease LaSota lentogen vaccine in preparing bivalent vaccine used to prevent rabies and Newcastle diseases.

A genetically engineered rabies virus vaccine with the E1 and E3 deficient recombinant defective human adenovirus as carrier is disclosed. The rabies virus coated glucoprotein encoding gene and the element to regulate it for efficient expression are carried in the E1 region. The said encoding gene comes from the rabies virus CVS-N2C with strong neurovirulence.